Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 17, 2022 | Negev Capital Announces Final Close of $30M+ for Fund One, Set to Back Psychedelic Drug Development Startups | Negev Capital is an early stage VC fund. Negev Capital invests in companies that develop novel drugs for neuropsychiatric disorders, based on psychedelic compounds. 40% of total capital has been deployed into 20 companies. Toronto, Ontario-... |
| Aug 16, 2021 | Psychedelic mushrooms to treat rare headache: Oxford startup lands $80M | Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced it has successfully completed an oversubscribed Series B financing, ra... |
| Psychedelic mushrooms to treat rare headache: Oxford startup lands $80M | Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced it has successfully completed an oversubscribed Series B financing, ra... |
Reviews 0
FAQ about Neveg Capital
What has the press written about Neveg Capital?
Parsers VC has collected 4 articles mentioning Neveg Capital, among them “Negev Capital Announces Final Close of $30M+ for Fund One, Set to Back Psychedelic Drug Development Startups” (Jan 17, 2022) and “Psychedelic mushrooms to treat rare headache: Oxford startup lands $80M” (Aug 16, 2021).
Is Neveg Capital still active?
Yes, Neveg Capital is active; its latest activity on Parsers VC dates from Jan 17, 2022.